Company intelligence / Profile preview

Mitra Biotech

Ownership: Private
Development stage: Other

Overview

Mitra Biotech develops the CANscript™ ex vivo tumor microenvironment modeling system that predicts individual patient responses to cancer therapies. This enables more effective personalized treatment selection and accelerates oncology drug development. Their technology has shown strong correlation with actual patient outcomes. They collaborate globally—including partnerships with Brigham and Women’s Hospital—to advance next-generation immunotherapies such as engineered oncolytic viruses for brain tumors like glioblastoma multiforme.

Therapeutic areas: Oncology
Modalities: Oncolytic virus therapySmall moleculeBiologic
Industry: Biotech

Partnerships

Brigham and Women’s Hospital / Harvard Medical School Department of Neurosurgery—for evaluation of novel engineered HSV‑1-based oncolytic viruses in GBM patients using the CANscript™ platform

Beyond the preview

Go deeper on Mitra Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mitra Biotech.